Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
BIOGEN INC.: Biogen Inc. amended its bylaws effective July 28, 2023 to (i) clarify that nominees for election or reelection must agree to adhere to Biogen's Code of Business Conduct and Corporate Governance Principles and (ii) remove the position of Vice Chair and add the position of Chair Pro Tem (effective 2023-07-28).
- Change
- bylaw amendment
- Effective
- 2023-07-28
Exact text from the filing
Effective July 28, 2023, the Board of Directors of Biogen approved an amendment to Biogen's Fourth Amended and Restated Bylaws (the “ Fourth Amended and Restated Bylaws ”) to (i) clarify that nominees for election or reelection must agree to, among other things, adhere to Biogen’s Code of Business Conduct and Corporate Governance Principles and (ii) remove the position of Vice Chair and add the position of Chair Pro Tem.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
BIOGEN INC. entered into Agreement and Plan of Merger with Reata Pharmaceuticals, Inc. valued at $172.50 in cash (effective 2023-07-28).
- Action
- entry
- Agreement
- merger
- Counterparty
- Reata Pharmaceuticals, Inc.
- Value
- $172.50 in cash
- Effective
- 2023-07-28
Exact text from the filing
On July 28, 2023, Biogen Inc. (“ Biogen ”), River Acquisition, Inc. (“ Merger Sub ”), a Delaware corporation and a wholly-owned subsidiary of Biogen and Reata Pharmaceuticals, Inc. (“ Reata ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), pursuant to which, and upon the terms and subject to the conditions set forth therein, Merger Sub will be merged with and into Reata (the “ Merger ”), with Reata surviving the Merger as a wholly-owned subsidiary of Biogen.
View on SEC.gov